On March 15, 2023 Dxcover Limited, a clinical-stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, reported the upcoming presentation of new data on its liquid biopsy platform at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in Orlando, Florida from April 14-19 (Press release, Dxcover, MAR 15, 2023, View Source [SID1234628850]). The poster presentation will outline data from a preclinical study evaluating the Dxcover Cancer Liquid Biopsy platform’s capabilities to detect advanced adenomas and early cases of colorectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The future of cancer care will depend on reliable and comprehensive methods to detect malignancies earlier, enabling easier treatment and lower rates of recurrence for patients," said Matthew J. Baker, Ph.D., co-founder and Chief Technical Officer of Dxcover. "Dxcover’s proprietary liquid biopsy technology combines novel infrared spectroscopy with artificial intelligence in order to rapidly detect cancers with ideal specificity and sensitivity, and I look forward to sharing the latest data on our platform’s potential to detect cancers early."

Presentation details:

Title: Early colorectal cancer detection with a spectroscopic liquid biopsy
Abstract Number: 6506
Session Title: Early Detection and Molecular Markers of Prevention
Session Date and Time: Wednesday Apr 19, 2023 9:00 AM – 12:30 PM
Location: Orange County Convention Center, Poster Section 28

On March 15, 2023 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported two upcoming poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting 2023 (April 14-19) in Orlando, Florida (Press release, Hummingbird Bioscience, MAR 15, 2023, View Source [SID1234628849]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present a poster describing the efficacy of HMBD-001, a clinical-stage anti-HER3 mAb currently in Phase 1a clinical trial (NCT05057013), across multiple preclinical models of squamous cell carcinomas and a poster demonstrating the efficacy and tolerability of HMBD-501, a next generation HER3-targeting antibody-drug conjugate (ADC), in preclinical solid tumor models.

The poster for HMBD-001 highlights that inhibition of HER3 has broad applicability in squamous cell carcinomas and this anti-tumor activity can be enhanced with concurrent inhibition of EGFR, with significant potential to improve patient outcomes. Robust tumor growth inhibition in various preclinical squamous cancer models, including lung, esophageal and head and neck, is observed with HMBD-001 when used as monotherapy and in combination with cetuximab. The HMBD-501 poster discusses the rational design of the HER3 ADC, its potentially best-in-class safety and tolerability profiles, and superior inhibition of tumor growth compared to other HER3 ADCs, across a range of preclinical cancer models.

"We are excited to be on the cusp of the new horizon of therapies for HER3-expressing cancers. At AACR (Free AACR Whitepaper), we will have the first publication of preclinical results for our potentially best-in-class HER3 ADC," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. "The potent anti-tumor activity we see from our clinical-stage HMBD-001 program is exciting and represents a broad treatment opportunity due to conserved sensitivity to HER3 and EGFR inhibition across multiple squamous carcinomas. We look forward to discussing the promising data for our novel HER3-targeting therapeutics with the oncology research community at AACR (Free AACR Whitepaper)."

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody Technologies

Session Date and Time: Monday Apr 17, 2023 1:30 PM – 5:00 PM ET

Location: Poster Section 13

HMBD-001 Presentation

Title: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected preclinical models of squamous cell carcinomas

Poster Board Number: 27

Published Abstract Number: 2659

HMBD-501 Presentation

Title: HMBD-501 – a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in preclinical solid tumor models

Poster Board Number: 28

Published Abstract Number: 2660

On March 15, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 14-19, 2023 (Press release, Jazz Pharmaceuticals, MAR 15, 2023, View Source [SID1234628848]). Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca (lurbinectedin), zanidatamab and JZP898.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data Jazz and our partners are presenting at AACR (Free AACR Whitepaper) this year demonstrate our commitment to advancing the next generation of oncology care, including our ongoing research for lurbinectedin," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "Over the last year, Jazz has added promising new immuno-oncology and targeted therapy candidates to our pipeline – including zanidatamab, a novel late-stage HER2-targeted bispecific antibody – and progressed ongoing development programs with the goal of improving standards of care across multiple cancer types with significant unmet need and poor outcomes."

Data highlights at the AACR (Free AACR Whitepaper) Annual Meeting include:

A poster presentation evaluating the role of SLFN11 expression in predicting response to lurbinectedin, a DNA damaging agent, in human small cell lung cancer (SCLC) cell lines and in vivo models. Results demonstrate that efficacy may be correlated to SLFN11 protein expression, consistent with the RNA level association.1
A poster presentation featuring data identifying MCL1 as a specific lurbinectedin target and demonstrating anti-tumor activity of lurbinectedin in combination with a specific BCL2 inhibitor and with a specific BCL2L1 inhibitor in in vivo and in vitro models.2
A poster presentation titled "ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers."
The AACR (Free AACR Whitepaper) abstracts are available at: View Source!/10828/

The full list of Jazz-supported presentations at the 2023 AACR (Free AACR Whitepaper) Annual Meeting are:

Zepzelca (lurbinectedin) Presentations

Presentation Title

Author

Presentation Details

High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models

Gupta A., et al.

Type: Poster

Session: Biomarkers of Therapeutic Benefit 2

Date: Monday, April 17, 2023, 9:00 AM – 12:30 PM

Abstract number: 2145

Lurbinectedin exhibits combinatorial activity with BCL2/BCL2L1 inhibitors in vitro and in vivo by modulation of MCL1 expression

Vaidya K.S., et al.

Type: Poster

Session: Cell Death Pathways/ Molecular Classifications of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes

Date: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM

Abstract number: 6155

Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response

Diez M.M., et al.

Type: Poster

Session: DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents

Date: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM

Abstract number: 6247

Zanidatamab Presentation*

Presentation Title

Author

Presentation Details

ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers

Shpektor D., et al.

Type: Poster

Session: Phase I Clinical Trials 2

Date: Tuesday, April 18, 2023, 1:30 PM – 5:00 PM

Abstract number: CT278

*Clinical trial abstract texts are embargoed until noon ET on April 14, 2023.

JZP898 Presentation

Presentation Title

Author

Presentation Details

WTX-613, (JZP898) a selectively activated IFNα INDUKINE molecule, reprograms the tumor microenvironment and generates robust anti-tumor immunity as a monotherapy and in combination with checkpoint inhibitors

Nirschl CJ, et al.

Type: Poster

Session: Immunomodulatory Agents and Interventions 1

Date: Monday April 17, 2023 9:00 AM – 12:30 PM

Abstract number: 1817

On March 15, 2023 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 14-19, 2023, in Orlando, Florida (Press release, Compugen, MAR 15, 2023, View Source [SID1234628847]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"One of the biggest challenges in bringing new treatments to cancer patients, is understanding the complex disease biology," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "Single cell technology has revolutionized the study of cell populations, particularly immune cells and has been a key technology used by many scientists involved in cancer immunotherapy research. The research we are presenting at AACR (Free AACR Whitepaper) identified an inaccuracy in the single cell gene model technology. By correcting the GENCODE gene model, the most widely used gene model in single cell analysis platforms, we believe that we are enabling a more accurate detection of PVRIG, thereby facilitating the advancement of worldwide research of this pathway. We believe that this advancement could lead to the development of new cancer immunotherapies. As a leader in the DNAM-1 axis space, targeting both PVRIG and TIGIT pathways, we are focused on proof-of-concept studies in cancer patients treated with the triple combination of our potential first-in-class anti-PVRIG, COM701 our potential best-in-class anti-TIGIT, COM902, and a PD-1 inhibitor, with the goal of maximizing clinical benefit for patients."

Poster details:

Session Date and Time: Tuesday April 18, 2023, 9:00 AM – 12:30 PM ET
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Algorithms and Statistical Methods
Poster Title: Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance
Published Abstract Number: 4292

The abstract is available on Compugen’s website at www.cgen.com

On March 15, 2023 Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, reported that the first clinical data for a cancer treatment targeting the Hippo pathway will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 (Press release, Vivace Therapeutics, MAR 15, 2023, View Source [SID1234628846]). Results from the company’s Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, will be presented by Timothy A. Yap, Ph.D., of the University of Texas, M.D. Anderson Cancer Center, during an oral plenary session at the conference. The AACR (Free AACR Whitepaper) conference is being held April 14-19, 2023, in Orange, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 study (View Source) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural malignant mesothelioma. The study included both a dose escalation and a dose expansion phase, the latter of which also enrolled patients with neurofibromatosis 2 (NF2) mutant tumors.

Details of the oral presentation at the AACR (Free AACR Whitepaper) conference are as follows:

Presentation #CT006:

Title: First-in-Class, First-in-Human Phase 1 Trial of VT3989, an inhibitor of Yes-Associated Protein (YAP)/Transcriptional Enhancer Activator Domain (TEAD), in Patients (pts) with Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors with Neurofibromatosis 2 (NF2) Mutations

Presenting Author: Timothy A. Yap, Ph.D., University of Texas, M.D. Anderson Cancer Center

Session: CTPL02: Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents

Date/Time: Sunday, April 16, 2023, 3:30 – 3:45 p.m. Eastern

Location: W Hall A2-3
Vivace’s proprietary compounds, including lead development candidate VT3989, inhibit palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. Pre-clinical research and development activities have demonstrated that VT3989 is active as a monotherapy against tumors that rely upon dysfunction of the Hippo pathway, and in combination with other anti-cancer therapies in additional tumor types.